Fibrosis-4 (FIB-4) Index and mortality in COVID-19 patients admitted to the emergency departmentArticle Published on 2022-09-012022-11-15 Journal: Internal and Emergency Medicine [Category] 바이오마커, [키워드] 95% CI 95% confidence interval adjusted hazard ratio ALT Analysis AST AUC cohort study coronavirus COVID-19 COVID-19 patient Cox regression cut-off Department disease Emergency Endpoint FIB-4 fibrosis Fibrosis-4 High-flow oxygen identify increased mortality index Liver damage Liver fibrosis. liver transaminase log-rank test mechanical ventilation Mortality mortality risk Patient performed predict Predictive Prognosis ROC analysis ROC Curve secondary to define were used worse prognosis [DOI] 10.1007/s11739-022-02997-9 PMC 바로가기
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial계층적 복합 종점을 기반으로 한 연구의 설계 및 분석: DARE-19 시험의 통찰력Article Published on 2022-09-012022-09-11 Journal: Therapeutic innovation & regulatory science [Category] 임상, [키워드] accompanied Analysis analyzed cardiometabolic Cardiometabolic risk factors clinical endpoint Clinical endpoints Clinical outcome clinical outcomes clinically component components Composite composite endpoint COVID-19 COVID-19 pneumonia Dapagliflozin described detectable disease Effect Endpoint example flexible handling Hierarchical composite endpoints hospitalized patient hospitalized patients ICH include inhibitor insight Interpretation mechanism mechanism of action Missing data offered Pneumonia power primary endpoints randomized trial ranking Sample size SGLT2 inhibitors statistical suggested the primary endpoint therapeutic to define Treatment Trial Win odds. with COVID-19 [DOI] 10.1007/s43441-022-00420-1 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 studyClinical Trial Published on 2022-09-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI Administered Adults adverse event age all age group antibody baseline Bharat Biodefense children clinical conducted COVID-19 vaccine curtail deaths decrease demonstrated dose Efficacy eight eligible Endpoint enrolled female Fever for inclusion geometric mean GMT ratio GMTs group groups healthy children hospital Hyderabad immunogenicity immunosuppressive inactivated Inactivated vaccine India Infection injection site pain intramuscular dose less Local local reaction male Mild Mild-to-moderate multicentre neutralisation test neutralising antibody response neutralising antibody titre no difference Open-label Pain pandemic participant Phase 2 study phase 2/3 platform positive PRNT Reactions reactogenicity reduction Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine second dose Serious Adverse Events seroconverted serology test serum sample severity of COVID-19 susceptible Symptom three group titre Trial were excluded Withdrawal [DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial
Analytical Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 VariantArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] SARS, 변종, 치료기술, [키워드] Ag-RDT Ag-RDTs analytical sensitivity Antigen-detecting rapid diagnostic tests Biological Breakthrough infection circulating clinical sample comparable COVID-19 cultured virus Delta detect detectable diagnostic diagnostic test duplicate eight Endpoint generate Infection prevention investigated Measures omicron Omicron variant Omicron-BA.1 variant performed positive Rapid Rapid diagnostic test retrospective Retrospective study SARS-CoV-2 SARS-CoV-2 variant sensitivity Seven Test vaccinated individual variant variants of concern variants of concern. VoC VOCs [DOI] 10.1128/spectrum.00853-22 PMC 바로가기
Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infectionsReview article Published on 2022-08-262022-10-05 Journal: The Lancet. Infectious Diseases [Category] 임상, [키워드] Administered analysed Analysis BCG children COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 vaccines Effect effective Effects Endpoint ENhance Health Heterologous host immune system immune response Immunity incidence individual Infection infections Live attenuated vaccine lymphocyte response modify non-specific observational study occur Older overall mortality pandemic Patient Placebo randomised controlled trial receiving researcher respiratory infection revaccination second sequence Severity of infection Sex subgroup analysis to define Trial Vaccine vaccine administration Vaccines View [DOI] 10.1016/S1473-3099(22)00498-4 [Article Type] Review article
Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant periodArticle Published on 2022-08-252022-11-15 Journal: Frontiers in Immunology [Category] 진단, [키워드] 95%CI absence analyzed Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers ARBs blocker Care CCI Charlson comobidity index clinician Comorbidity Coronavirus disease 2019 COVID-19 COVID-19 patient cut-off value died discharged dominant echocardiographic Endpoint greater help high-risk patient Hospital admission Hospitalization Hospitalized hospitalized COVID-19 patient hospitalized patient in-hospital mortality Infection inhibitor Laboratory laboratory-confirmed males Mortality mortality risk Neutrophil-to-lymphocyte ratio Neutrophil-to-lymphocyte ratio. NLR Older omicron Patient physical predict predicted predictor Prevalence prognostic indicator Radiographic receptor reduce risk stratification significantly the primary endpoint therapy [DOI] 10.3389/fimmu.2022.958418 PMC 바로가기
Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study코로나바이러스 질병 2019(COVID-19) 환자 치료를 위한 렘데시비르 플러스 덱사메타손 대 덱사메타손 단독 요법: 보충 O2 요법이 필요한 환자: 전향적 통제된 비무작위 연구Controlled Clinical Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제, [키워드] 30-Day mortality Antiviral baseline calculated clinical outcomes cohorts Combination Controlled coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRP D-dimer Dexamethasone drug effective Endpoint enrolled evaluate evaluated faster fibrinogen FiO2 group groups Hospitalization IMPROVE independent Inflammatory inflammatory markers Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory characteristics log-rank test median Mortality neutrophil neutrophil/lymphocyte ratio no differences occurred primary endpoint primary endpoints Prospective reducing mortality reduction in reduction in mortality Remdesivir Respiratory failure Respiratory function Sample size SARS-CoV-2 clearance secondary Secondary endpoints shown significant difference significant differences survival the log-rank test therapy treat Treatment viral clearance Viral clearance. were used [DOI] 10.1093/cid/ciac014 PMC 바로가기 [Article Type] Controlled Clinical Trial
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition Research Published on 2022-08-222022-10-05 Journal: Nature Medicine [Category] 변종, 비임상, 유전자 메커니즘, 임상, 진단, 치료기술, 치료제, [키워드] acquisition antibody average Biomarker circulating Concentration Dilution Efficacy Endpoint half-lives HIV-1 immunodeficiency in vitro Infection inhibitory Mediated neutralization potency neutralizing antibody predict predicted prevented prevention reduce regimen regimens required serum Serum Neutralization sustained Trial Vaccines virus viruses [DOI] 10.1038/s41591-022-01953-6 [Article Type] Research
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients – the randomized, EU-wide, placebo-controlled, phase II study design of IXIONClinical Trial Published on 2022-08-192022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] addition Administered Admission capillary Capillary leak Clinical management clinical study code coronavirus COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity Deterioration disease Disease progression double-blinded drop-out Endothelial dysfunction Endpoint enrolled EudraCT Europe France FX06 Germany Hospital stay Hospitalization Hospitalized hospitalized patient Human ICU Inflammation. intravenously Italy lack limitation Lithuania Lung function mammals Mild moderate multicentre Non-intubated occurred outbreak oxygen saturation Patient patient recruitment patients patients receiving placebo peptide per day Placebo placebo-controlled Portugal positive SARS-CoV-2 PCR Potential Prevent prevent disease progression primary endpoint problem proportion protocol randomization Randomized receiving recruitment reduce Romania SARS-CoV-2 secondary Spain stages standard care Study design subject survival systemic inflammation the WHO therapy while [DOI] 10.1186/s13063-022-06609-x PMC 바로가기 [Article Type] Clinical Trial
Potential of Egg as Complementary Food to Improve Nutrient Intake and Dietary DiversityRandomized Controlled Trial Published on 2022-08-182022-10-04 Journal: Nutrients [Category] 임상, [키워드] adjusted allergy cholesterol Community complementary contribute control group COVID-19 determine dietary dietary diversity dietary intake Diversity Effect Egg egg allergy egg consumption eight Endpoint feasibility Follow-up food Frequency growth incidence Infants infants. intake lockdown nutrient Potential Randomized controlled trial regression analysis remained South Africa Symptoms vitamin B6 [DOI] 10.3390/nu14163396 PMC 바로가기 [Article Type] Randomized Controlled Trial